Cristina Saura
VIEW MORE
Recently published in The New England Journal of Medicine1 results of a phase 3, double-blind, randomized trial show that the...
Addition of PI3K inhibition could improve outcomes in patients with PIK3CA-mutated metastatic breast cancer
Elena Garralda VHIO
VIEW MORE
The journal Nature has published the results of a clinical trial led by researchers from the Clínica Universidad de Navarra...
Blocking the GDF-15 protein may rescue resistance to immunotherapy against solid tumours
Cristina Saura
VIEW MORE
The phase 3 EMBER-3 trial is evaluating imlunestrant, a next-generation oral selective estrogen receptor degrader (SERD), alone or in combination...
Next-generation SERD imlunestrant significantly improves progression-free survival in patients with ER+/HER2- advanced breast cancer compared to standard therapy

Latest News

Cristina Saura

Recently published in The New England Journal of Medicine1 results of a phase 3, double-blind, randomized trial show that the...

23 December 2024
Addition of PI3K inhibition could improve outcomes in patients with PIK3CA-mutated metastatic breast cancer
Recently published in The New England Journal of Medicine1 results of a phase 3, double-blind, randomized trial show that the...
+
Elena Garralda VHIO

The journal Nature has published the results of a clinical trial led by researchers from the Clínica Universidad de Navarra...

18 December 2024
Blocking the GDF-15 protein may rescue resistance to immunotherapy against solid tumours
The journal Nature has published the results of a clinical trial led by researchers from the Clínica Universidad de Navarra...
+
Cristina Saura

The phase 3 EMBER-3 trial is evaluating imlunestrant, a next-generation oral selective estrogen receptor degrader (SERD), alone or in combination...

11 December 2024
Next-generation SERD imlunestrant significantly improves progression-free survival in patients with ER+/HER2- advanced breast cancer compared to standard therapy
The phase 3 EMBER-3 trial is evaluating imlunestrant, a next-generation oral selective estrogen receptor degrader (SERD), alone or in combination...
+
Mafalda Oliveira exterior con bata VHIO

The results of the SOLTI-2103 VALENTINE clinical trial demonstrate that the antibody drug conjugate (ADC) patritumab deruxtecan at the standard...

11 December 2024
Patritumab deruxtecan reduces serious side effects in breast cancer patients compared to conventional chemotherapy while maintaining treatment efficacy
The results of the SOLTI-2103 VALENTINE clinical trial demonstrate that the antibody drug conjugate (ADC) patritumab deruxtecan at the standard...
+
VIEW MORE NEWS

PRINCIPAL RESEARCHERS

Diseño sin título (16)
Cristina Saura
Breast Cancer & Melanoma Group

The main area of expertise of the Breast Cancer Group is clinical research focused on drug development and associated translational…

+
Dr. Elena Garralda UITM Caixa Research VHIO
Elena Garralda
Early Clinical Drug Development Group

We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and…

+
Teresa Macarulla VHIO
Teresa Macarulla
Gastrointestinal and Endocrine Tumors Group

Our group continues to play an essential role in developing molecular therapies against GI malignancies. We make important contributions to…

+
VHIO Alena Gros
Alena Gros
Tumor Immunology and Immunotherapy Group

Our group focuses on better understanding the naturally occurring T-cell response to cancer and establishing ways to exploit these antitumor…

+

Events

Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.
Privacy Policy
You have read and agreed to our privacy policy
Required